Skip to main content

Advertisement

SpringerLink
Log in

The Cell Biology of TRIM5α

  • The Science of HIV (AL Landay, Section Editor)
  • Published:
Current HIV/AIDS Reports Aims and scope Submit manuscript

Abstract

The tripartite motif (TRIM)–containing proteins are involved in many cellular functions such as cell signaling, apoptosis, cell differentiation, and immune modulation. TRIM5 proteins, including TRIM5α and TRIM-Cyp, are known to possess antiretroviral activity against many different retroviruses. Besides being retroviral restriction factors, TRIM5 proteins participate in other cellular functions that have recently emerged in the study of TRIM5α. In this review, we discuss properties of TRIM5α such as cytoplasmic body formation, protein turnover, and trafficking. Also, we discuss recent insights into innate immune modulation mediated by TRIM5α, highlighting the various functions TRIM5α has in cellular processes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature. 2004;427:848–53.

    Article  PubMed  CAS  Google Scholar 

  2. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, et al. The tripartite motif family identifies cell compartments. Embo J. 2001;20:2140–51.

    Article  PubMed  CAS  Google Scholar 

  3. Diaz-Griffero F, Qin XR, Hayashi F, Kigawa T, Finzi A, Sarnak Z, et al. A B-box 2 surface patch important for TRIM5alpha self-association, capsid binding avidity, and retrovirus restriction. J Virol. 2009;83:10737–51.

    Article  PubMed  CAS  Google Scholar 

  4. Li X, Sodroski J. The TRIM5alpha B-box 2 domain promotes cooperative binding to the retroviral capsid by mediating higher-order self-association. J Virol. 2008;82:11495–502.

    Article  PubMed  CAS  Google Scholar 

  5. Li X, Song B, Xiang SH, Sodroski J. Functional interplay between the B-box 2 and the B30.2(SPRY) domains of TRIM5alpha. Virology. 2007;366:234–44.

    Article  PubMed  CAS  Google Scholar 

  6. Adams SR, Campbell RE, Gross LA, Martin BR, Walkup GK, Yao Y, et al. New biarsenical ligands and tetracysteine motifs for protein labeling in vitro and in vivo: synthesis and biological applications. J Am Chem Soc. 2002;124:6063–76.

    Article  PubMed  CAS  Google Scholar 

  7. Javanbakht H, Yuan W, Yeung DF, Song B, Diaz-Griffero F, Li Y, et al. Characterization of TRIM5alpha trimerization and its contribution to human immunodeficiency virus capsid binding. Virology. 2006;353:234–46.

    Article  PubMed  CAS  Google Scholar 

  8. Kar AK, Diaz-Griffero F, Li Y, Li X, Sodroski J. Biochemical and biophysical characterization of a chimeric TRIM21-TRIM5alpha protein. J Virol. 2008;82:11669–81.

    Article  PubMed  CAS  Google Scholar 

  9. Langelier CR, Sandrin V, Eckert DM, Christensen DE, Chandrasekaran V, Alam SL, et al. Biochemical characterization of a recombinant TRIM5alpha protein that restricts human immunodeficiency virus type 1 replication. J Virol. 2008;82:11682–94.

    Article  PubMed  CAS  Google Scholar 

  10. Mische CC, Javanbakht H, Song B, Diaz-Griffero F, Stremlau M, Strack B, et al. Retroviral restriction factor TRIM5alpha is a trimer. J Virol. 2005;79:14446–50.

    Article  PubMed  CAS  Google Scholar 

  11. Li X, Yeung DF, Fiegen AM, Sodroski J. Determinants of the Higher Order Association of the Restriction Factor TRIM5{alpha} and Other Tripartite Motif (TRIM) Proteins. J Biol Chem. 2011;286:27959–70.

    Article  PubMed  CAS  Google Scholar 

  12. Sastri J, O'Connor C, Danielson CM, McRaven M, Perez P, Diaz-Griffero F, et al. Identification of residues within the L2 region of rhesus TRIM5alpha that are required for retroviral restriction and cytoplasmic body localization. Virology. 2010;405:259–66.

    Article  PubMed  CAS  Google Scholar 

  13. Stremlau M, Perron M, Welikala S, Sodroski J. Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. J Virol. 2005;79:3139–45.

    Article  PubMed  CAS  Google Scholar 

  14. Yap MW, Nisole S, Stoye JP. A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol. 2005;15:73–8.

    Article  PubMed  CAS  Google Scholar 

  15. Sawyer SL, Wu LI, Emerman M, Malik HS. Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proc Natl Acad Sci U S A. 2005;102:2832–7.

    Article  PubMed  CAS  Google Scholar 

  16. Johnson WE, Sawyer SL. Molecular evolution of the antiretroviral TRIM5 gene. Immunogenetics. 2009;61:163–76.

    Article  PubMed  CAS  Google Scholar 

  17. Nakayama EE, Shioda T. Anti-retroviral activity of TRIM5 alpha. Rev Med Virol. 2010;20:77–92.

    Article  PubMed  CAS  Google Scholar 

  18. Sastri J, Campbell EM. Recent insights into the mechanism and consequences of TRIM5alpha retroviral restriction. AIDS Res Hum Retroviruses. 2011;27:231–8.

    Article  PubMed  CAS  Google Scholar 

  19. Newman RM, Hall L, Kirmaier A, Pozzi LA, Pery E, Farzan M, et al. Evolution of a TRIM5-CypA splice isoform in old world monkeys. PLoS Pathog. 2008;4:e1000003.

    Article  PubMed  Google Scholar 

  20. Sayah DM, Sokolskaja E, Berthoux L, Luban J. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature. 2004;430:569–73.

    Article  PubMed  CAS  Google Scholar 

  21. Virgen CA, Kratovac Z, Bieniasz PD, Hatziioannou T. Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species. Proc Natl Acad Sci U S A. 2008;105:3563–8.

    Article  PubMed  CAS  Google Scholar 

  22. Wilson SJ, Webb BL, Ylinen LM, Verschoor E, Heeney JL, Towers GJ. Independent evolution of an antiviral TRIMCyp in rhesus macaques. Proc Natl Acad Sci U S A. 2008;105:3557–62.

    Article  PubMed  CAS  Google Scholar 

  23. Diaz-Griffero, F., A. Kar, M. Perron, S. H. Xiang, H. Javanbakht, X. Li, and J. Sodroski. 2007. Modulation of Retroviral Restriction and Proteasome Inhibitor-resistant Turnover by Changes in the TRIM5{alpha} B-box 2 Domain. J Virol.

  24. Diaz-Griffero F, Li X, Javanbakht H, Song B, Welikala S, Stremlau M, et al. Rapid turnover and polyubiquitylation of the retroviral restriction factor TRIM5. Virology. 2006;349:300–15.

    Article  PubMed  CAS  Google Scholar 

  25. Diaz-Griffero F, Vandegraaff N, Li Y, McGee-Estrada K, Stremlau M, Welikala S, et al. Requirements for capsid-binding and an effector function in TRIMCyp-mediated restriction of HIV-1. Virology. 2006;351:404–19.

    Article  PubMed  CAS  Google Scholar 

  26. Nepveu-Traversy ME, Berube J, Berthoux L. TRIM5alpha and TRIMCyp form apparent hexamers and their multimeric state is not affected by exposure to restriction-sensitive viruses or by treatment with pharmacological inhibitors. Retrovirology. 2009;6:100.

    Article  PubMed  Google Scholar 

  27. Diaz-Griffero F, Kar A, Lee M, Stremlau M, Poeschla E, Sodroski J. Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp. Virology. 2007;369:400–10.

    Article  PubMed  CAS  Google Scholar 

  28. • Ganser-Pornillos, B. K., V. Chandrasekaran, O. Pornillos, J. G. Sodroski, W. I. Sundquist, and M. Yeager. 2011. Hexagonal assembly of a restricting TRIM5alpha protein. Proc Natl Acad Sci U S A 108:534-9. This paper visualized the TRIM5α lattice, mediated by the ability of TRIM5α to self-associate, which likely forms around restriction-sensitive viral capsids.

    Article  PubMed  CAS  Google Scholar 

  29. Campbell EM, Dodding MP, Yap MW, Wu X, Gallois-Montbrun S, Malim MH, et al. TRIM5 alpha cytoplasmic bodies are highly dynamic structures. Mol Biol Cell. 2007;18:2102–11.

    Article  PubMed  CAS  Google Scholar 

  30. • Campbell, E. M., O. Perez, J. L. Anderson, and T. J. Hope. 2008. Visualization of a proteasome-independent intermediate during restriction of HIV-1 by rhesus TRIM5alpha. J Cell Biol 180:549-61. This paper visualized the association between TRIM5α cytoplasmic bodies during restriction, demonstrating that the ability of TRIM5α to self associate around viral complexes, manifested at the formation of cytoplasmic bodies, plays an important role in retroviral restriction.

    Article  PubMed  CAS  Google Scholar 

  31. Song B, Diaz-Griffero F, Park DH, Rogers T, Stremlau M, Sodroski J. TRIM5alpha association with cytoplasmic bodies is not required for antiretroviral activity. Virology. 2005;343:201–11.

    Article  PubMed  CAS  Google Scholar 

  32. Perez-Caballero D, Hatziioannou T, Zhang F, Cowan S, Bieniasz PD. Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity. J Virol. 2005;79:15567–72.

    Article  PubMed  CAS  Google Scholar 

  33. • Pertel, T., S. Hausmann, D. Morger, S. Zuger, J. Guerra, J. Lascano, C. Reinhard, F. A. Santoni, P. D. Uchil, L. Chatel, A. Bisiaux, M. L. Albert, C. Strambio-De-Castillia, W. Mothes, M. Pizzato, M. G. Grutter, and J. Luban. 2011. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 472:361-5. This study identified the connection between the ability of TRIM5 proteins to restrict retroviral infection and its ability to associate with proteins involved in signal transduction, most notably TAK1.

    Article  PubMed  CAS  Google Scholar 

  34. Tareen SU, Emerman M. Human Trim5alpha has additional activities that are uncoupled from retroviral capsid recognition. Virology. 2011;409:113–20.

    Article  PubMed  CAS  Google Scholar 

  35. Dyck JA, Maul GG, Miller Jr WH, Chen JD, Kakizuka A, Evans RM. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell. 1994;76:333–43.

    Article  PubMed  CAS  Google Scholar 

  36. Puvion-Dutilleul F, Chelbi-Alix MK, Koken M, Quignon F, Puvion E, de The H. Adenovirus infection induces rearrangements in the intranuclear distribution of the nuclear body-associated PML protein. Exp Cell Res. 1995;218:9–16.

    Article  PubMed  CAS  Google Scholar 

  37. Weis K, Rambaud S, Lavau C, Jansen J, Carvalho T, Carmo-Fonseca M, et al. Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell. 1994;76:345–56.

    Article  PubMed  CAS  Google Scholar 

  38. Lallemand-Breitenbach V, de The H. PML nuclear bodies. Cold Spring Harb Perspect Biol. 2010;2:a000661.

    Article  PubMed  Google Scholar 

  39. Everett RD, Chelbi-Alix MK. PML and PML nuclear bodies: implications in antiviral defence. Biochimie. 2007;89:819–30.

    Article  PubMed  CAS  Google Scholar 

  40. Geoffroy MC, Chelbi-Alix MK. Role of promyelocytic leukemia protein in host antiviral defense. J Interferon Cytokine Res. 2011;31:145–58.

    Article  PubMed  CAS  Google Scholar 

  41. Dong S, Stenoien DL, Qiu J, Mancini MA, Tweardy DJ. Reduced intranuclear mobility of APL fusion proteins accompanies their mislocalization and results in sequestration and decreased mobility of retinoid X receptor alpha. Mol Cell Biol. 2004;24:4465–75.

    Article  PubMed  CAS  Google Scholar 

  42. Rivera OJ, Song CS, Centonze VE, Lechleiter JD, Chatterjee B, Roy AK. Role of the promyelocytic leukemia body in the dynamic interaction between the androgen receptor and steroid receptor coactivator-1 in living cells. Mol Endocrinol. 2003;17:128–40.

    Article  PubMed  CAS  Google Scholar 

  43. Chen YC, Kappel C, Beaudouin J, Eils R, Spector DL. Live cell dynamics of promyelocytic leukemia nuclear bodies upon entry into and exit from mitosis. Mol Biol Cell. 2008;19:3147–62.

    Article  PubMed  CAS  Google Scholar 

  44. Eskiw CH, Dellaire G, Mymryk JS, Bazett-Jones DP. Size, position and dynamic behavior of PML nuclear bodies following cell stress as a paradigm for supramolecular trafficking and assembly. J Cell Sci. 2003;116:4455–66.

    Article  PubMed  CAS  Google Scholar 

  45. Short KM, Cox TC. Subclassification of the RBCC/TRIM superfamily reveals a novel motif necessary for microtubule binding. J Biol Chem. 2006;281:8970–80.

    Article  PubMed  CAS  Google Scholar 

  46. McDonald D, Vodicka MA, Lucero G, Svitkina TM, Borisy GG, Emerman M, et al. Visualization of the intracellular behavior of HIV in living cells. J Cell Biol. 2002;159:441–52.

    Article  PubMed  CAS  Google Scholar 

  47. Diaz-Griffero F, Gallo DE, Hope TJ, Sodroski J. Trafficking of some old world primate TRIM5alpha proteins through the nucleus. Retrovirology. 2011;8:38.

    Article  PubMed  CAS  Google Scholar 

  48. Arriagada G, Muntean LN, Goff SP. SUMO-interacting motifs of human TRIM5alpha are important for antiviral activity. PLoS Pathog. 2011;7:e1002019.

    Article  PubMed  CAS  Google Scholar 

  49. Wu X, Anderson JL, Campbell EM, Joseph AM, Hope TJ. Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proc Natl Acad Sci U S A. 2006;103:7465–70.

    Article  PubMed  CAS  Google Scholar 

  50. Anderson JL, Campbell EM, Wu X, Vandegraaff N, Engelman A, Hope TJ. Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins. J Virol. 2006;80:9754–60.

    Article  PubMed  CAS  Google Scholar 

  51. Rold CJ, Aiken C. Proteasomal degradation of TRIM5alpha during retrovirus restriction. PLoS Pathog. 2008;4:e1000074.

    Article  PubMed  Google Scholar 

  52. O'Connor C, Pertel T, Gray S, Robia SL, Bakowska JC, Luban J, et al. p62/sequestosome-1 associates with and sustains the expression of retroviral restriction factor TRIM5alpha. J Virol. 2010;84:5997–6006.

    Article  PubMed  Google Scholar 

  53. Christian F, Anthony DF, Vadrevu S, Riddell T, Day JP, McLeod R, et al. p62 (SQSTM1) and cyclic AMP phosphodiesterase-4A4 (PDE4A4) locate to a novel, reversible protein aggregate with links to autophagy and proteasome degradation pathways. Cell Signal. 2010;22:1576–96.

    Article  PubMed  CAS  Google Scholar 

  54. Geetha T, Seibenhener ML, Chen L, Madura K, Wooten MW. p62 serves as a shuttling factor for TrkA interaction with the proteasome. Biochem Biophys Res Commun. 2008;374:33–7.

    Article  PubMed  CAS  Google Scholar 

  55. Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR, Wooten MW. Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol. 2004;24:8055–68.

    Article  PubMed  CAS  Google Scholar 

  56. Johansen T, Lamark T. Selective autophagy mediated by autophagic adapter proteins. Autophagy. 2011;7:279–96.

    Article  PubMed  CAS  Google Scholar 

  57. El Bougrini J, Dianoux L, Chelbi-Alix MK. PML positively regulates interferon gamma signaling. Biochimie. 2011;93:389–98.

    Article  PubMed  CAS  Google Scholar 

  58. Gack MU, Shin YC, Joo CH, Urano T, Liang C, Sun L, et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature. 2007;446:916–20.

    Article  PubMed  CAS  Google Scholar 

  59. Ishii T, Ohnuma K, Murakami A, Takasawa N, Yamochi T, Iwata S, et al. SS-A/Ro52, an autoantigen involved in CD28-mediated IL-2 production. J Immunol. 2003;170:3653–61.

    PubMed  CAS  Google Scholar 

  60. Kim JY, Ozato K. The sequestosome 1/p62 attenuates cytokine gene expression in activated macrophages by inhibiting IFN regulatory factor 8 and TNF receptor-associated factor 6/NF-kappaB activity. J Immunol. 2009;182:2131–40.

    Article  PubMed  CAS  Google Scholar 

  61. Kong HJ, Anderson DE, Lee CH, Jang MK, Tamura T, Tailor P, et al. Cutting edge: autoantigen Ro52 is an interferon inducible E3 ligase that ubiquitinates IRF-8 and enhances cytokine expression in macrophages. J Immunol. 2007;179:26–30.

    PubMed  CAS  Google Scholar 

  62. Ryu YS, Lee Y, Lee KW, Hwang CY, Maeng JS, Kim JH, et al. TRIM32 protein sensitizes cells to tumor necrosis factor (TNFalpha)-induced apoptosis via its RING domain-dependent E3 ligase activity against X-linked inhibitor of apoptosis (XIAP). J Biol Chem. 2011;286:25729–38.

    Article  PubMed  CAS  Google Scholar 

  63. Shi M, Deng W, Bi E, Mao K, Ji Y, Lin G, et al. TRIM30 alpha negatively regulates TLR-mediated NF-kappa B activation by targeting TAB2 and TAB3 for degradation. Nat Immunol. 2008;9:369–77.

    Article  PubMed  CAS  Google Scholar 

  64. Yu S, Gao B, Duan Z, Xu W, Xiong S. Identification of tripartite motif-containing 22 (TRIM22) as a novel NF-kappaB activator. Biochem Biophys Res Commun. 2011;410:247–51.

    Article  PubMed  CAS  Google Scholar 

  65. Yamauchi K, Wada K, Tanji K, Tanaka M, Kamitani T. Ubiquitination of E3 ubiquitin ligase TRIM5 alpha and its potential role. FEBS J. 2008;275:1540–55.

    Article  PubMed  CAS  Google Scholar 

  66. Lienlaf M, Hayashi F, Di Nunzio F, Tochio N, Kigawa T, Yokoyama S, et al. Contribution of E3-Ubiquitin Ligase Activity to HIV-1 Restriction by TRIM5{alpha}rh: Structure of the RING Domain of TRIM5{alpha}. J Virol. 2011;85:8725–37.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, 2160 South First Avenue, Maywood, IL, 60153, USA

    Zana Lukic & Edward M. Campbell

Authors
  1. Zana Lukic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edward M. Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edward M. Campbell.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lukic, Z., Campbell, E.M. The Cell Biology of TRIM5α. Curr HIV/AIDS Rep 9, 73–80 (2012). https://doi.org/10.1007/s11904-011-0102-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-011-0102-8

Keywords

Search

Navigation